A Single-Arm, Multicenter, Open-label Phase III Expansion Trial Evaluating Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A
Latest Information Update: 23 Oct 2024
Price :
$35 *
At a glance
- Drugs FRSW 107 (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms RH-107-III02
- Sponsors Zhengzhou Gensciences
- 24 Aug 2023 Status changed from recruiting to completed.
- 19 Apr 2021 New trial record